European Medicine Agency Grants Theratechnologies an Additional Month to Complete Responses Related to Trogarzo® Application

May 24, 2019
PDF Version
Supporting Materials:
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it requested and obtained from the European Medicines Agency (EMA) an additional month to address new questions received yesterday in regard to the establishment of a post-approval registry to gather long-term data on patients taking Trogarzo® (ibalizumab) in Europe.